Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 20 de 39 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Slomski A. Avoiding hypoglycemia at all costs is crucial for some with diabetes. JAMA 2013;309:2536-7. [Ref.ID 95732]
2. Cita con resumen
Anónimo. HbA1c targets in type 2 diabetes: guidelines and evidence. Drug Ther Bull 2013;51:42-5. [Ref.ID 95196]
3. Cita con resumen
Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, MacMahon SC, Cooper ME, Hamet P, Marre M, Mogensen CE, Poulter N, Mancia G, Cass A, Patel A, Zoungas S. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013;83:517-23. [Ref.ID 95115]
5.
García-Bragado F. La medicina actual ante los anticoagulantes de nueva generación. Med Clin (Barc) 2012;138:438-40. [Ref.ID 92561]
6. Cita con resumen
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011;343:1136. [Ref.ID 91918]
7.
Rowe IA, Mutimer DJ. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. BMJ 2011;343:1060-3. [Ref.ID 91842]
8. Cita con resumen
Badgett R, Dong F, Aung K. Plotting surrogate outcomes. Arrow plots show way forward. BMJ 2011;343:654. [Ref.ID 91722]
9.Enlace a cita original
Anónimo. Insulin use may increase mortality in type 2 diabetes. MeReC rapid review 2010:15 de abril. [Ref.ID 88271]
10.
Psaty BM, Prentice RL. Variation in event rates in trials of patients with type 2 diabetes. JAMA 2009;302:1698-700. [Ref.ID 86982]
11.Tiene citas relacionadas Cita con resumen
Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72. [Ref.ID 85922]
12.Tiene citas relacionadas
Tamborlane WV, Beck RW. Continuous glucose monitoring in type 1 diabetes mellitus. Lancet 2009;373:1744-6. [Ref.ID 85912]
13. Cita con resumen
Lehman R. Tight control of blood glucose in long standing type 2 diabetes. BMJ 2009;338:901-2. [Ref.ID 85645]
14.Enlace a cita original
Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S, Hamet P, Poulter N, Lip GYH, Patel A, on behalf of the ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30:1128-35. [Ref.ID 85434]
16.Tiene citas relacionadas Cita con resumen
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Diabetes Care 2009;32:187-92. [Ref.ID 85102]
17.Tiene citas relacionadas Cita con resumen
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203. [Ref.ID 85101]
20. Cita con resumen
Home P. Tight control of blood glucose and cardiovascular disease. BMJ 2008;337:1007-8. [Ref.ID 84400]
Seleccionar todas
 
 1 a 20 de 39 siguiente >>